Skip to main content

LLS News Network

LLS News Network

The

The Leukemia & Lymphoma Society launches Impact Research grants to help underserved patients access to clinical trials

Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials

Read More
Covid-19

Covid-19 Vaccine Safety Among Blood Cancer Patients

Background and Purpose

Because of the health emergency created by the COVID-19 virus, three COVID-19 vaccinations have been authorized by the U.S. FDA for Emergency Use Administration (EUA). The vaccine clinical trials were streamlined and essentially excluded people with a current or past diagnosis of cancer. Therefore, how people with blood cancer respond to the COVID-19 vaccinations is unknown.

Read More

LLS TAP announces five new investments supporting next generation immunotherapies

RYE BROOK, N.Y., April 22, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers. LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.

Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org. An LLS representative will respond as soon as possible.